February 16, 2022 10:50 AM EST
Pharma

Putting its piv­otal fail­ure in the rearview mir­ror, As­traZeneca scores an EU nod for its lu­pus drug

Nicole DeFeudis

Editor

Af­ter a bumpy road to ap­proval in the US, As­traZeneca is tout­ing a nod for Saph­ne­lo in the EU to treat mod­er­ate to se­vere sys­temic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

'No mir­a­cles': What Re­gen­eron's George Yan­copou­los re­al­ly thinks of AI

Chi­nese start­up be­gins first tri­al of in vi­vo CRISPR ther­a­py for blood dis­ease

RFK Jr. says he’ll di­vest in­ter­ests in CRISPR Ther­a­peu­tics if con­firmed for HHS chief

GLP-1s can cut the risk of Alzheimer’s. What does that mean for No­vo Nordisk?

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times